Anticoagulation therapy: Reducing factor XI with antisense oligonucleotides superior to endoxaparin for postoperative venous thromboembolism

Nature Reviews Cardiology

Volumn 12, Issue 2, 2015, Pages 66-

  Duarte, João H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BLOOD CLOTTING FACTOR 11; ENOXAPARIN; MESSENGER RNA; ANTICOAGULANT AGENT; OLIGONUCLEOTIDE;

ANTICOAGULANT THERAPY; ANTISENSE THERAPY; BLEEDING; DRUG EFFICACY; DRUG SAFETY; HEMOSTASIS; HUMAN; NOTE; OUTCOME ASSESSMENT; PHLEBOGRAPHY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK REDUCTION; SURGICAL PATIENT; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; FEMALE; KNEE ARTHROPLASTY; MALE; POSTOPERATIVE COMPLICATIONS; VENOUS THROMBOSIS;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, KNEE; FACTOR XI; FEMALE; HUMANS; MALE; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; POSTOPERATIVE COMPLICATIONS; VENOUS THROMBOSIS;

EID: 84923190605     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2014.214     Document Type: Note

References (2)

1. Büller, H. R. et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N. Engl. J. Med. doi:10.1056/NEJMoa1405760
2. Flaumenhaft, R. Making (anti)sense of factor XI in thrombosis. N. Eng. J. Med. doi:10.1056/NEJMe1413874